Clinical Trials Logo

Clinical Trial Summary

Registry of patients with Primary Cutaneous Lymphoma seen at participating centers in Spain. The registry will identify patients with this disease and includes information about stage, diagnostic and therapeutic interventions and willingness to participate in further studies.


Clinical Trial Description

Registry of patients with Primary Cutaneous Lymphoma seen at participating centers in Spain. The registry will identify patients with this disease and includes information about stage, diagnostic and therapeutic interventions and willingness to participate in further studies. Data is entered in the registry in each of the participating cutaneous lymphoma clinics. These data are updated at least yearly. Participants receive specific training before starting, and there is an online continuous monitoring system. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03646422
Study type Observational [Patient Registry]
Source Fundación Academia Española de Dermatología
Contact Ignacio Garcia-Doval, MD, PhD, MScEpid
Phone +34 91 544 62 84
Email investigacion@AEDV.ES
Status Recruiting
Phase
Start date September 1, 2016
Completion date January 1, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05540340 - A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant N/A
Completed NCT03415399 - Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma Phase 1
Withdrawn NCT03605589 - Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma Phase 1
Recruiting NCT04807881 - Phase Ib Clinical Study of Keynatinib Phase 1
Recruiting NCT05510596 - Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity Syndrome N/A
Not yet recruiting NCT06350994 - Early Assessment of Cardiac Function After Treatment With CAR-T Cells
Terminated NCT02670317 - Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients. Phase 2
Completed NCT00998946 - Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma Phase 2
Terminated NCT00768339 - A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas Phase 1/Phase 2
Terminated NCT00521638 - Study Evaluating TRU-015 in B-Cell Non-Hodgkin's Lymphoma Phase 1
Withdrawn NCT00538096 - A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma Phase 1
Completed NCT00379574 - Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL Phase 1/Phase 2
Completed NCT00156013 - Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL) Phase 1/Phase 2
Completed NCT00147121 - Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203) Phase 2/Phase 3
Recruiting NCT04594798 - A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL Phase 2
Recruiting NCT04161248 - Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Early Phase 1
Withdrawn NCT04052061 - QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma Phase 1
Recruiting NCT04884035 - Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma Phase 1
Not yet recruiting NCT05834426 - Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers
Recruiting NCT05376709 - A Mixed Methods Study of Nutrition Practice in Cancer Care on Non-Hodgkin Lymphoma Population N/A